Back to Search
Start Over
Recent advances in understanding and treating chronic granulomatous disease [version 1; referees: 4 approved]
- Source :
- F1000Research. 6:F1000 Faculty Rev-1427
- Publication Year :
- 2017
- Publisher :
- London, UK: F1000 Research Limited, 2017.
-
Abstract
- A number of recent advances have been made in the epidemiology and treatment of chronic granulomatous disease. Several reports from developing regions describe the presentations and progress of local populations, highlighting complications due to Bacillus Calmette–Guérin vaccination. A number of new reports describe complications of chronic granulomatous disease in adult patients, as more survivors reach adulthood. The complications experienced by X-linked carriers are particularly highlighted in three new reports, confirming that infection and inflammatory or autoimmune conditions are more common and severe than previously recognised. Finally, definitive treatment with haematopoietic stem cell transplantation and gene therapy is reviewed.
- Subjects :
- Review
Articles
Bacterial Infections
Cellular Microbiology & Pathogenesis
Clinical Immunology
Endocrine & Metabolic Pharmacology
Environmental Microbiology
Fungal Infections
Gastrointestinal Physiology
Genetics of the Immune System
Immunity to Infections
Immunopharmacology & Hematologic Pharmacology
Inflammatory Bowel Disease
Innate Immunity
Leukocyte Development
Medical Genetics
Medical Microbiology
Respiratory Infections
Stem Cells & Regeneration
chronic granulomatous disease
haematopoietic stem cell transplantation
gene therapy
inflammatory bowel disease
X-linked carrier disease
Subjects
Details
- ISSN :
- 20461402
- Volume :
- 6
- Database :
- F1000Research
- Journal :
- F1000Research
- Notes :
- Editorial Note on the Review Process F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version). The referees who approved this article are: John Gallin, National Institutes of Health, Bethesda, MD, USA No competing interests were disclosed. Dirk Roos, Sanquin Research, Amsterdam, Netherlands Competing interests: Andrew Gennery wrote two chapters for a book edited by Dirk Roos Andrea Finocchi, University of Rome Tor Vergata/Bambino Gesù Children's Hospital, Unit of Immunoinfectivology, Rome, Italy No competing interests were disclosed. Nizar Mahlaoui, Immuno-Haematology and Rheumatology Unit, Necker Enfants Malades Hospital, University Paris Descartes, Paris, France Competing interests: Nizar Mahlaoui and Andrew Gennery have previously collaborated on large multicentre studies for hematopoietic cell transplantation (PMID: 28392333, 25595268) and are both on the board of the European Society for Immunodeficiencies., , [version 1; referees: 4 approved]
- Publication Type :
- Academic Journal
- Accession number :
- edsfor.10.12688.f1000research.11789.1
- Document Type :
- review
- Full Text :
- https://doi.org/10.12688/f1000research.11789.1